Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Utah Medical Products (UTMD) Asset Writedowns and Impairment (2016 - 2025)

Utah Medical Products (UTMD) has 16 years of Asset Writedowns and Impairment data on record, last reported at $402000.0 in Q3 2025.

  • For Q3 2025, Asset Writedowns and Impairment changed N/A year-over-year to $402000.0; the TTM value through Sep 2025 reached $397000.0, up 5062.5%, while the annual FY2024 figure was -$4000.0, 87.88% up from the prior year.
  • Asset Writedowns and Impairment reached $402000.0 in Q3 2025 per UTMD's latest filing, up from $2000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $402000.0 in Q3 2025 and bottomed at -$27000.0 in Q2 2023.
  • Average Asset Writedowns and Impairment over 5 years is $22888.9, with a median of $2000.0 recorded in 2021.
  • Peak YoY movement for Asset Writedowns and Impairment: soared 500.0% in 2021, then crashed 900.0% in 2024.
  • A 5-year view of Asset Writedowns and Impairment shows it stood at $4000.0 in 2021, then skyrocketed by 125.0% to $9000.0 in 2022, then crashed by 122.22% to -$2000.0 in 2023, then soared by 200.0% to $2000.0 in 2024, then surged by 20000.0% to $402000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Asset Writedowns and Impairment were $402000.0 in Q3 2025, $2000.0 in Q2 2025, and -$9000.0 in Q1 2025.